Plasma cell neoplasms:

1- Multiple myeloma:
-derived from bone marrow stem or B-Lymphocyte lineage. Location: jaw , gingiva, palate, floor of the mouth.

. Age : Rarely encountered before the fifth decade of life. appears at a mean age of 63 years. Gender : It has a slight male predominance.

Clinical features:

Assymptomatic or may produce pain Swelling Expansion Numbness Mobility of teeth Weakness, weight loss anemia 10% develop systemic amiloidosis

Hystopathologic features:
composed of monotonous proliferation of neoplastic plasma cells Abundant plassma cells within bone marrow

Radiographic features:
multiple sharpy punched-out but noncorticated radiolucent areas of bone destruction in the jaws.

differential diagnosis:
- metastatic carcinoma -lymphoma Langerhans cell disease

Treatment:
- chemotherapeutic alkylating agents and steroids with local radiation directed to painful bone lesions . -Bone transplantation.

Prognosis:
-overall median survival time is related to the stage of disease. Stage 1 more than 60 months Stage 3 23 months - most patients with myeloma die of infection , renal failure , disseminated myeloma , cardiac complications or hematologic complications of hemorrage or thrombosis.

Histopathology:
Microscopically, all clinical manifestations of plasma cell tumors are similar.

2-Solitary Plasmacytoma of Bone:

Location: - ileum , femure , humerus, thoracic vertebrae and skull - rare in the jaws (angle of the mandible) Age: disease of a childhood Mean age : 50 years old

 Gender: male predilection Clinical features : 30% to 75% of cases of solitary plasmacytoma of bone eventually progresses to multiple myeloma

Histopathologic features:
have normal peripheral blood picture and a normal differential and clinical chemistry profile.

Histopathologic appearance indicated to multiple myeloma

Radiographic features:
Well-defined lytic lesion that may be multilocular , resembling the appearance of central giant cell granuloma.

 Treatment : Local radiotherapy Surgical excision followed by radiation Prognosis: 10% to 15% of patients have local recurrence Overal survival time is 10 years.